Natco Pharma Share Price in Focus on 35.75% Stake Purchase in Adcock Ingram for ₹2,000 Crore

Natco Pharma has announced a cash offer to acquire a 35.75% stake in Adcock Ingram Holdings Ltd, South Africa, for around ₹2,000 crore. This includes a prior holding of 0.80%, taking the total to 35.75%. The company will purchase over 5.16 crore shares at ZAR 75.00 per share.

The deal will be funded entirely through Natco’s internal accruals. It includes public share acquisition and treasury shares or fresh issuance by Adcock Ingram. The total investment covers the transaction amount and related expenses.

Post-Deal Shareholding and Delisting

Once completed, Natco will become the 2nd-largest shareholder after Bidvest Group, which holds 64.25%. Following the acquisition, Adcock Ingram will be delisted from the Johannesburg Stock Exchange and continue operating as a private entity.

Company Profiles

Adcock Ingram, founded in 1890, is a key name in South Africa’s pharmaceutical sector. It holds around 10% of the private market and is the largest supplier of hospital and critical care products in the country. It recorded revenues of ZAR 9.6 billion for FY24.

Subsidiary Plans

Natco will also incorporate a new wholly-owned subsidiary in South Africa, NATCO Pharma South Africa Proprietary Limited, with an investment of up to ₹2,100 crore. Meanwhile, its existing subsidiary, Time Cap Overseas Ltd, will be liquidated.

Read more: Best Pharma Stocks in July 2025: Based on 5-Year CAGR!

Regulatory Approvals

The deal has been approved by both companies’ boards and is pending regulatory clearances from the Reserve Bank of India and South Africa’s Takeover Regulation Panel. Completion is expected within four months, subject to approvals.

Natco Pharma Share Price Performance

As of 10:52 AM on July 24, 2025, Natco Pharma share price was trading at ₹1,009.95, a 2.41% decrease. The stock is down 26% YTD but has gained nearly 19% over the past month. 

Conclusion

The acquisition adds a major international investment to Natco’s portfolio and signals further operational expansion in the South African market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.